Navigation Links
AtheroNova Adds New Medical Advisor
Date:4/11/2013

IRVINE, Calif., April 11, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Stephen Nicholls , M.B.B.S., PhD., Heart Disease Theme leader at the South Australia Health and Medical Research Institute (SAHMRI), has been appointed as chair of the newly renamed Clinical Advisory Board, replacing the recently retired Dr. Giorgio Zadini , one of the co-founders of AtheroNova.  Dr. Nicholls will also be a Co-Principal Investigator in the Company's upcoming clinical trials.

"As we continue to make positive strides, this is a key step in our evolution from a pre-clinical to a clinical stage pharmaceutical company as we move toward entry into Phase 1 in the near future.  Dr. Nicholls brings a wealth of experience in the imaging and analysis of cardiovascular plaque as we target the treatment of both serum cholesterol as well as atherosclerosis with AHRO-001," stated Thomas W. Gardner , CEO of AtheroNova. "Dr. Nicholls' experience with clinical developments during his time at the Cleveland Clinic as well as his new role as the key theme leader in one of the premier research organizations in Australia is essential in leading our Clinical Advisory Board.  We would like to thank Dr. Zadini for all of his tremendous efforts and accomplishments as the key medical advisor of the Company during the development stage and wish him well."

"Steve is one of the world's most respected authorities in the imaging of atherosclerosis," commented Mark Wedel , M.D., Chief Medical Officer of AtheroNova.  "We are profoundly fortunate and appreciative to benefit from his leadership and expertise as we move forward.
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
2. AtheroNova Names New Director
3. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
4. AtheroNova Releases 2011 Financial Results
5. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
6. AtheroNova Announces a New Board Member
7. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
8. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
11. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... of Darmstadt, Germany, has initiated a global Phase 3 ... with hormone receptor-positive, locally advanced, recurrent or metastatic breast ... developed by Merck KGaA under a license agreement with ...
... , , , , SINGAPORE, June 22 ... The EU,s commitment to achieve a reduction in CO2 emissions by ... of a target of 5.75 percent bio-fuels of all transportation fuel ... States is a smaller market, it is witnessing rapid growth in ...
... BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. ... will be presenting a scientific poster describing L-DOS47 analytical ... Pharmaceutical Scientists ("AAPS") National Biotechnology Conference, which runs from ... and Trade Center in Seattle, Washington. , ...
Cached Biology Technology:Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 4Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 3Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 4Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 2Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 3Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 4Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 5
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... University paleobiologist Gregory M. Erickson sliced up some ... an international team of scientists identify a new ... only subtle similarities, the FSU researcher determined that ... North America's hulking Tyrannosaurus rex. , Make that ...
... the once almost universally fatal childhood cancer acute lymphoblastic ... future, thanks to improvements in diagnosis and treatment over ... Jude Children's Research Hospital. Almost 4,000 cases of ALL ... two-thirds of which are in children and adolescents, making ...
... and Geoff Garnett (of Imperial College London) suggests that ... controlled through antiretroviral drugs alone, even if universal access ... the open-access international medical journal PLoS Medicine, without additional ... about safe sex, access to drugs is likely to ...
Cached Biology News:FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 2FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 3St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Access to antiretrovirals unlikely to reduce HIV infection rates 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: